ArticleIn vivo (Athens, Greece)
Stratifying Skin Cancer Patients and Guiding Treatment Decisions Through Combined p53 and p63 Expression Analysis.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimSkin cancer, particularly non-melanocytic types like squamous and basal cell carcinoma, remains a growing concern. The tumor suppressor proteins p53 and p63 play key roles in skin carcinogenesis. This study aimed to assess the differential expression of p53 and p63 in various stages of chemically-induced skin cancer. MATERIALS AND
methodsFVB/N mice, aged 44 weeks, were randomly assigned into three groups: a control group (n=8) and two experimental groups (Group A: n=16, Group B: n=16). The study employed a two-stage carcinogenesis procedure, which involved an initial application of 97.4 nmol DMBA to shaved skin on the back, followed by applications of 32.4 nmol TPA after thirteen weeks for Group A and after twenty weeks for Group B. The control group did not receive any treatment. Skin lesions were monitored, and tissue samples were collected for histological and immunohistochemical analysis.
resultsp53 expression was significantly elevated in precancerous and benign tumors compared to normal histology (47.6% and 47.8%
conclusionDistinct expression patterns of p53 and p63 suggest stage-specific roles in skin carcinogenesis. Elevated p53 in early lesions supports its tumor-suppressive function, while p63 may contribute to tumor maintenance in advanced stages. These findings support the utility of p53 and p63 as biomarkers for diagnosis and prognosis in skin cancer, and potential targets for future therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.